A Trial of AN0025 With Chemoradiation Therapy in Stage III NSCLC Participants
Status:
Not yet recruiting
Trial end date:
2028-06-01
Target enrollment:
Participant gender:
Summary
Primary
- Evaluate safety and toxicity of AN0025 in both the consolidative setting (after
chemoradiation) and in the concurrent setting (during chemoradiation)
- Evaluate efficacy by progression-free survival (PFS), objective response rate (ORR), and
time to death or distant metastasis (TTMD), Duration of response (DOR), Overall survival
(OS) with the addition of AN0025 in both the consolidative and concurrent settings
Exploratory
- Evaluate pharmacokinetics of AN0025 in conjunction with chemoradiation, and then with
durvalumab